TENDER NO. BMSIC/DRUGS/18-04

Check list - I: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name Shiva Biogenetic Pharmaceuticals Pvt. Ltd._____ Total Number of Pages Submitted in bid documents_

Sl. No	SBD clause serial No	Descrption of the Clause/ Technical Eligibility Criteria as per SBD as mentioned in the Check List	Document/ fees submission status (Yes/ No)	Page number	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3. (a)	**Tender Fee (Non –Refundable) of Rs 10,000/- in form of Demand Draft** drawn in Favor of "Managing Director, Bihar Medical Services and Infrastructure Corporation Limited" payable at Patna. This fee is payable only once for one tender irrespective of items contained therein.	yes	65	yes	
2	3.(b)	Bidder are required to submit **Earnest Money Deposit in the form of Demand Draft / Bank Guarantee** drawn in favor of Managing Director, Bihar Medical Services and Infrastructure Corporation Limited from any Scheduled/Nationalized bank payable at Patna as follows:- Upto 5 drugs- Rs1,00,000/- (One Lakh only), for 6 to 10 drugs- Rs 2,00,000/- (Two Lakh only), for 11 to 20 drugs- Rs 3,00,000/-(Three Lakh only) and for More than 20 drugs Rs 5,00,000/- (Five Lakh only)	yes	1	yes	
3	3.(c)	Documentary evidence of the **constitution of the company/ firm/ Proprietorship such as Memorandum and Articles of Association, Partnership Deed** etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.	yes	10-35	yes	
4	3.(d)	The **details of Bidder** Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	yes	136	yes	
5	3.(e)	**Power of Attorney or Resolution of Board** by which the **authorised signatory** has been authorised by bidder firm to sign the documents. As per Clause 3(e) of the NIT. **Format to be used.**	yes	04-Mar	yes	
6	3.(l)	Copies of the **Audited Balance Sheet and Profit and Loss statement** showing details of their annual average turnover not less than **25 Crores** for any three of the last four consecutive financial years (Auditor/CA certificate of turnover will not be accepted). **Self-attested copies** are to be submitted.	yes	127-126,66-67&78-79	yes	

Chandan Kumar 14/7/18

7	3.(m)	Copy of **Income Tax Return for any three of last four Consecutive Assessment years** should be submitted **(self-attested)**.	**yes**	**58-60**	**yes**	
8	3.(p)	**Copy of PAN Card of the bidder company should be submitted (self-attested).**	**yes**	**5**	**yes**	
9	3.(q)	**Copy of certificate of valid Sales Tax/VAT and GST registration of the bidder company should be submitted (self-attested).**	**yes**	**61-63**	**yes**	

Chandan Kumar Jha
14/7/18

TENDER NO. BMSIC/DRUGS/18-04

Check list - II: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name: SHIVA BIOGENITIC PHRAMCEUTICALS PVT. LTD. **Total Number of Pages Submitted in bid documentS - 177**

Sl. No	SBD Clause serial No	Descrption of the Clause/ Technical Eligibility Criteria as per SBD, as mentioned in Check List	Document submission status (Yes/ No)	Page Number as number submitted by BMSICL	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3.(d)	The **details of Bidder** Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	Yes	136	Yes	-
2	3.(e)	**Power of Attorney or Resolution of Board** by which the **authorised signatory** has been authorised by bidder firm to sign the documents. As per Clause 3(e) of the NIT. **Format to be used.**	Yes	03, 04	Yes	-
3	3.(f)	Minimum **three years old valid Manufacturing License of the product quoted with latest license renewal certificate**.	Yes	98, 99,101	Yes	-
4		**Approved product list as per the license issued for quoted drugs for minimum three years.**	Yes	As mentioned in check list III 36-55 & 105-113	Yes Please find the remarks.	(i) Except NIT sl. No. 227 & 109 issues date is 06.06.2018. (ii) Generic name of Approved product of NIT sl. No. 03, 103, 24, ,25, 151, 152, 166, 227, 61 &109 do not comply for minimum three years. (iii) Approved product name of NIT sl. No. 03, 103, 24, 25, 151, 152, 56, 166, 61 & 109 is also in Brand name and valid upto 27.04.2017 (iv) For NIT Sl. no.-56 dosage Form as per approval is only in Tablet (Not Gastro-resistant Tablet)
5		**Manufacturing License** along with approved product list must be **valid till the last date of the submission of tender.**	Yes	98,99 & 101	Yes	
6		In Case of those drugs which are notified first time in IP 2014 then Manufacturing and Marketing license should be in any official compendium (USP/BP/IP) along with current valid License in IP in continuation.	Yes	42-46	Yes	IP-2014) comply for NIT sl. 234, 118, 119,122, 123.
7		**Market standing certificate & Manufacturing certificate** issued by the Licensing Authority as a Manufacturer **for each drug quoted** for the **last 3 years** (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organisation).	Yes	07-09/ 95-97 & 98,99,101	Yes Please find the remarks.	MSC of all quoted products(only in generic form) submitted. But approval date of generic name of NIT sl. No. 03, 103, 24, 25, 151, 152, 166 & 61 issued on 03.05.2017 and for NIT sl .no. 227 & 109 issued on 06.06.2018
8		If permission in **Form 46 (For manufacturers) / Form 45 (For Importers) from DCGI** has been obtained, then the **3 years manufacturing/ Import & Market standing clause will be relaxed**. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable.	N.A	N.A	N.A	-

14/07/18

9		For **all regulated products,** the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCG (I) shall be required for all new regulated products to this effect.	**N.A**	**N.A**	**N.A**	-
10		FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable	**N.A**	**N.A**	**N.A**	-
		NOTE: Bidders shall submit self-attested copies of required manufacturing license and approved product list in support of above mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.	**Yes**	**98, 99, 101 & 36-55, 105-113**	**Yes**	**Some approved products are highlighted but many of them not highlighted**
11	**3.(g)**	In case of Importer, the bidder (importer) firm must have minimum three years old valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product are being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.	**N.A**	**N.A**	**N.A**	-
12	**3.(h)**	Bidder must have Market Standing Certificate (in India) of minimum three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. **Self-attested copies** are to be submitted.	**Yes**	**07-09**	**Yes**	**MSC of all quoted products (only in generic name) submitted. But approval date of generic name of NIT sl. No. 03, 103, 24, 25, 151, 152, 166 & 61 issued on 03.05.2017 and for NIT sl .no. 227 & 109 issued on 06.06.2018**

14/07/18

P.T.O.

13	3.(i)	Non Conviction Certificate (NCC) issued by the concerned Licensing Authority from Drugs Control Administration of the state for last three years should be submitted. It should be not more than one year old. **Self-attested copies** are to be submitted. For Surgicals In case of Non-Drug item "the bidder shall submit an affidavit on Non-Judicial stamp paper stating that the quoted product is not covered under Drugs & Cosmetics Act."	**Yes**	**6**	**Yes**	-
14	3.(j)	WHO-GMP/GMP (Good Manufacturing Practice) as per revised Schedule-'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/ Drugs Control Department. The GMP certificate must not be older than one year from the last date of submission of tender. **Self-attested copies** are to be submitted.	**Yes**	**64**	**Yes**	-
15	3.(k)	**Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority from Drugs Control Department** highlighting the **quoted product** section. **Self-attested copies** are to be submitted. In case of Importer An affidavit (With Stamp) sworn before first class magistrate/Notary stating the batch production capacity of the firm and also that said production(Importing) capacity shall be adequate for requirement laid in NIT. Importer will have also to submit Invoices/Evidence of import in items of said product with quantity details.	**Yes**	**2**	**Yes**	-
16	3.(n)	**The tenderer should give an affidavit (with stamp) sworn before first class magistrate / Notary stating that the firm & its quoted product is not black listed currently (as on the date of submission of the tender) by Central Government / Central Government agencies/any state government or any of the state government agencies / or any Drug procurement agencies or by BMSICL as per Annexure-II.**	**Yes**	**93-94**	**Yes**	Whether Blacklisted or not **Not Blacklisted.**
17	3.(o)	**List of item quoted in prescribed format as per Annexure-III duly signed.**	**Yes**	**56-57**	**Yes**	-
18	5.(k)	An Affidavit (with stamp) regarding acceptance of tender conditions to be submitted by the bidding firm as per **Annexure-IV.**	**Yes**	**137**	**Yes**	-
19	5.(l)	**Filled check list as per given Annexure-VI to be submitted at the time of uploading the bid.**	**Yes**	**90-92**	**Yes**	**Documents are not arranged as per the check list. (Annexure VI)**
20	7.(c)	**Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.**	**Yes**	**4**	**Yes**	-
21	10.(c)	**If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.**	**N.A**	**N.A**	**N.A**	-
22	**Corrigendum point**	**A Notarized affidavit on a Rs 100/- Non-Judicial Stamp Paper representing that the offered price is the lowest price as compared to the Rates provided to their respective Distributors/ Dealers/ Wholesalers/ Carrying and Forwarding Agents/ Authorized depot sales point in the State of Bihar.**	**Yes**	**138**	**Yes**	-

14/07/18

TENDER NO. BMSIC/DRUGS/18-04

Check list - III: Evaluation sheet to be used for preliminary evaluation of technical bids

Company name - SHIVA BIOGENITIC PHRAMCEUTICALS PVT. LTD. **Total number of pages submitted in bid documents- 177**

Sheet to be used for verification of product approval and market standing

Sl. No	NIT Sl. No	Name of the Quoted Drug		Pharmacopoeial Specification/ Strength		Pack Size		Dosage Form		Approval Details			Last 3yrs market standing certificate/ New Drug
		As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	First Approval	Approved Upto	Approved in Brand /Generic Name	
1	3	Albendazole Tabet IP	(i) Seworm (ii) Albendagole Tablet IP .	400 mg.	400 mg.	10 x 10	Not mentioned	Tablet	chewable Tablet	(i)28/04/12 pg -55, sl. 02 (ii)03//05/17 pg.39, sl-03	(i)27-04-2017 (ii)26/04/22	(i)Brand (ii)Generic)	Pg- 9 ,Sl-01
2	103	Ibuprofen Tablet IP	(i) IBUSIB 200 pg . -48, Sl no. - 50 (ii) Ibuprofen Tablet IP pg. 110	200 mg.	200 mg.	10 x 10	Not mentioned	Tablet	Film coated Tablet	(i)24/08/12 pg -48, sl. 50 (ii)03//05/17 pg.110,sl-38	(i)27-04-2017 (ii)26/04/22	(i)Brand (ii)Generic)	Pg- 9 ,Sl-09
3	104	Ibuprofen syrup	Ibuprofen suspension	100 mg/5 ml.	100 mg/5 ml.	60 ml. Bottle	Not mentioned	suspension	suspension	08-06-2006 pg -107 sl - 08	(i)27-04-2022 (page - 107)	Generic)	pg-8, sl-18
4	24	Azithromycin Tablet IP	(i) Azisib 250 (pg 54) (ii)Azithromycin IP Tablet (pg -38)	250 mg.	250 mg.	10 x10	Not mentioned	Tablet	Tablet	(i)28/04/12 pg -54, sl. 39 (ii)03//05/17 pg.38,sl-01	(i)27-04-2017 (ii)26/04/22	(i)Brand (ii)Generic)	Pg- 9 ,Sl-02
5	25	Azithromycin Tablet IP	(i) Azisib 500 (pg 54) (ii)Azithromycin IP Tablet (pg -38)	500 mg	500 mg	10 x10	Not mentioned	Tablet	Tablet	(i)28/04/12 pg -54, sl. 40 (ii)03//05/17 pg.38,sl-02	(i)27-04-2017 (ii)26/04/22	(i)Brand (ii)Generic)	Pg- 9 ,Sl-03
6	151	Metronidazole Benzoate Oral Suspension IP	(i) Matro D suspension pg-53 , sl.-53 (ii) Metronidazole Benzoate oral Suspension IP pg.-37, sl.-03	40 mg/ ml	200 mg/5 ml	60 ml. Bottle	Not mentioned	suspension	suspension	(i)24-08-2012 Pg-53, Sl-53 (ii) 03-05-17 Pg-37 Sl-03	(i)27-04-2017 (ii)26/04/22	(i)Brand (ii)Generic)	Pg- 9 ,Sl-04
7	152	Metronidazole Tablet IP	(i) Metrozol 200 pg.-52, sl.-24 (ii) Metronidazole Tablet IP pg.-36, sl.-13	200 mg.	200 mg.	10x10	Not mentioned	Tablet	Tablet	(i)24-08-2012 Pg-52, Sl-24 (ii) 03.05.2017 pg. 36, sl. 13	(i)27-04-2017 (ii)26/04/22	(i)Brand (ii)Generic)	Pg- 9 ,Sl-05
8	56	Diclofenac Sodium Tablet I IP	Diclosib SR. pg-51, sl-38	50 mg.	50 mg.	10x10	Not mentioned	Gastoro Resistant Tablet	Tablet*	24-08-2012 pg-51, sl-38	4/27/2017	Brand	pg-9, sl-06

14/07/18

9	56	Ofloxacian Tablet IP	(i) Ofloxacin Tablet IP pg-39, sl. 09 (ii) Sibaflox pg-49, sl-92	200 mg	200 mg.	10x10	Not mentioned	Tablet	Tablet	(i) 03-05-17 pg-39, sl-09 (ii) 28-04-12 pg-49, sl-92	(i) 26-04-22 (ii) 27-04-17	(i) Generic (ii) Brand	pg-9, sl-8
10	227	Vitamin C Tablet	Ascorbic acid Tablet pg-107, sl-07	500 mg	500 mg	10x10	Not mentioned	Tablet	Tablet	IP 2018 06-06-18 pg-107, sl-07	4/27/2022	Generic	pg-8, sl-17
11	61	Dicyclomine HCL Tablets I	(i) Cyclospas pg-50, sl-69 (ii) Dicyclomine HCL Tablets IP pg-112, sl-67	10 mg.	10 mg.	10x10	Not mentioned	Tablet	Tablet	(i) 24-08-12 pg-50, sl-69 (ii) 03-05-17 pg-112,sl-67	(i) 27-04-17 (ii) 26-04-22	(i)Brand (ii)Generic)	Pg- 9 ,Sl-07
12	184	Paracetamol Oral Suspension IP	(i) Paracetamol oral suspension IP pg.-47, sl.-04 (ii) Paracetamol Paediatric oral Suspension IP pg-109	500 mg/5 ml	125 mg/5ml	15 ml bottle	Not mentioned	Drop	suspension	(i) 13-03-13 pg-47, sl-04 (ii) 03-05-17 Pg.- 109, sl. No.-46	(i) 27-04-17 (ii) 26-04-22	(i)Generic (ii)Generic)	pg-8, sl-10
13	73	Domperidone syrup IP	Domperidone Suspension IP pg-47, sl-2	1 mg/ml	1 mg/ml	30 ml bottle	Not mentioned	Syrup	suspension	13-03-13 pg-47, sl-02	27-04-22 pg-107	Generic	pg-8, sl-16
14	234	Zinc Sulphate Oral Solution	Zinc sulphate oral solution IP pg-46, sl-02	20 mg/5 ml	20 mg/5 ml	100 ml bottle	Not mentioned	Oral Solution	Oral Solution	IP 2014 08-01-14 pg-46, sl-02	27-04-22 pg-108, sl-01	Generic	pg-8, sl-11
15	121	Levocetrizine Dihydrochloride	Levocetirizine Tablet IP pg-41, 106	5 mg	5 mg	10x10	Not mentioned	Tablet	Tablet	(i) 01-06-2013 Pg. - 41 (ii) 03-05-2017 Pg. -106, sl.-73	(i) 27-04-2017 Pg. -41 (ii) 26-04-2022 Pg. -106	(i) Generic (ii) Generic	pg-7 sl-19
16	118	Levofloxacin Tablet IP	Levofloxacin Tablet IP pg. - 42	250 mg.	250 mg.	10x10	Not mentioned	Tablet	Tablet	IP- 2014 07-11-2014 Pg. -42	27-04-2022 Pg. - 108, sl 01	Generic	pg-8, sl-15
17	119	Levofloxacin Tablet IP	Levofloxacin Tablet IP pg. - 43	500mg	500 mg	10x10	Not mentioned	Tablet	Tablet	23-03-2013 pg.- 43, sl - 01	27-04-2022 Pg. - 108, sl - 04	Generic	pg-8, sl-14
18	122	Levosalbutamol Tablet	Levosalbutamol Tablet IP Pg. - 45	2mg	2 mg	10x10	Not mentioned	Tablet	Tablet	08-01-2014 pg. -45, sl-02	27-04-2022 Pg. - 108, sl - 02	Generic	pg-8, sl-12
19	123	Levosalbutamol Syrup	Levosalbutamol Syrup Pg.- 44, sl - 01	1 mg/5 ml	1 mg/5 ml	60 ml Bottle	Not mentioned	Syrup	Syrup	13-03-2013 Pg. - 44, sl - 01	27-04-2022 Pg. - 108, sl - 03	Generic	pg-8, sl-13
20	109	Iron and folic acid syrup	(i) Irofol syrup Pg. - 40 (ii) Ferric ammonium citrate and folic acid syrup pg. - 105	Elemental iron 20 mg.+ Folic acid 100 mcg per 5 ml.	Ferric ammonium citrate eq. to elemental Iron 20mg + folic acid 100 mcg per 5ml	60 ml Bottle	Not mentioned	Syrup	Syrup	(i) 13-09-2012 Pg.- 40 (ii) 06.06.2018 Pg. - 105	(i) 27-04-2017 pg. 40 (ii) 27-04-2022 pg. - 105	(i) Brand (ii) Generic	pg-7, sl-20
		Note:-* In the dosage form as per approval only in tablet form (Not Gastro-Resistant Tablet as NIT)											

14/07/18

TENDER NO. BMSIC/DRUGS/18-04

Check list - IV: Evaluation sheet to be used for preliminary evaluation of technical bids

Company name- SHIVA BIOGENITIC PHRAMCEUTICALS PVT. LTD. Total number of pages submitted in bid documents- 177

Sheet for verification of licence details

Sl. No	NIT Sl. No	Name of the Drug as per NIT	Manufacturer		Importer		Validity		GMP/ WHO GMP/ COPP (Import)	
			Forms Number	Manufacturing license Number	Forms Number	Import license Number	From	To	From	To
1	3	Albendazole Tabet IP	25, 28	MNB/07/528 MB/07/529	N/A	N/A	28-04-2007 28-04-2007	27-04-2022 27.04.2022	08-12-2017 Pg.- 64	07-12-2019 pg. -64
2	103	Ibuprofen Tablet IP	25, 28	MNB/07/528 MB/07/529	N/A	N/A	28-04-2007 28-04-2007	27-04-2022 27.04.2022	08-12-2017 Pg.- 64	07-12-2019 pg. -64
3	104	Ibuprofen syrup	25, 28	MNB/07/528 MB/07/529	N/A	N/A	28-04-2007 28-04-2007	27-04-2022 27.04.2022	08-12-2017 Pg.- 64	07-12-2019 pg. -64
4	24	Azithromiycin Tablet IP	25, 28	MNB/07/528 MB/07/529	N/A	N/A	28-04-2007 28-04-2007	27-04-2022 27.04.2022	08-12-2017 Pg.- 64	07-12-2019 pg. -64
5	25	Azithromiycin Tablet IP	25, 28	MNB/07/528 MB/07/529	N/A	N/A	28-04-2007 28-04-2007	27-04-2022 27.04.2022	08-12-2017 Pg.- 64	07-12-2019 pg. -64
6	151	Metronidazole Benzoate Oral Suspension IP	25, 28	MNB/07/528 MB/07/529	N/A	N/A	28-04-2007 28-04-2007	27-04-2022 27.04.2022	08-12-2017 Pg.- 64	07-12-2019 pg. -64
7	152	Metronidazole Tablet IP	25, 28	MNB/07/528 MB/07/529	N/A	N/A	28-04-2007 28-04-2007	27-04-2022 27.04.2022	08-12-2017 Pg.- 64	07-12-2019 pg. -64
8	56	Diclofenac Sodium Tablet IP	25, 28	MNB/07/528 MB/07/529	N/A	N/A	28-04-2007 28-04-2007	27-04-2022 27.04.2022	08-12-2017 Pg.- 64	07-12-2019 pg. -64
9	166	Ofloxacian Tablet IP	25, 28	MNB/07/528 MB/07/529	N/A	N/A	28-04-2007 28-04-2007	27-04-2022 27.04.2022	08-12-2017 Pg.- 64	07-12-2019 pg. -64
10	227	Vitamin C Tablet	25, 28	MNB/07/528 MB/07/529	N/A	N/A	28-04-2007 28-04-2007	27-04-2022 27.04.2022	08-12-2017 Pg.- 64	07-12-2019 pg. -64
11	61	Dicyclomine HCL Tablets IP	25, 28	MNB/07/528 MB/07/529	N/A	N/A	28-04-2007 28-04-2007	27-04-2022 27.04.2022	08-12-2017 Pg.- 64	07-12-2019 pg. -64

14/07/18

12	184	Paracetamol Oral Suspension	25, 28	MNB/07/528 MB/07/529	N/A	N/A	28-04-2007 28-04-2007	27-04-2022 27.04.2022	08-12-2017 Pg.- 64	07-12-2019 pg. -64
13	73	Domperidone syrup IP	25, 28	MNB/07/528 MB/07/529	N/A	N/A	28-04-2007 28-04-2007	27-04-2022 27.04.2022	08-12-2017 Pg.- 64	07-12-2019 pg. -64
14	234	Zinc Sulphate Oral Solution IP	25, 28	MNB/07/528 MB/07/529	N/A	N/A	28-04-2007 28-04-2007	27-04-2022 27.04.2022	08-12-2017 Pg.- 64	07-12-2019 pg. -64
15	121	Levocetrizine Dihydrochloridc IP	25, 28	MNB/07/528 MB/07/529	N/A	N/A	28-04-2007 28-04-2007	27-04-2022 27.04.2022	08-12-2017 Pg.- 64	07-12-2019 pg. -64
16	118	Levofloxacin Tablet IP (250 mg)	25, 28	MNB/07/528 MB/07/529	N/A	N/A	28-04-2007 28-04-2007	27-04-2022 27.04.2022	08-12-2017 Pg.- 64	07-12-2019 pg. -64
17	119	Levofloxacin Tablet IP (500 mg)	25, 28	MNB/07/528 MB/07/529	N/A	N/A	28-04-2007 28-04-2007	27-04-2022 27.04.2022	08-12-2017 Pg.- 64	07-12-2019 pg. -64
18	122	Levosalbutamol Tablet	25, 28	MNB/07/528 MB/07/529	N/A	N/A	28-04-2007 28-04-2007	27-04-2022 27.04.2022	08-12-2017 Pg.- 64	07-12-2019 pg. -64
19	123	Levosalbutamol Syrup	25, 28	MNB/07/528 MB/07/529	N/A	N/A	28-04-2007 28-04-2007	27-04-2022 27.04.2022	08-12-2017 Pg.- 64	07-12-2019 pg. -64
20	109	Iron and folic acid syrup	25, 28	MNB/07/528 MB/07/529	N/A	N/A	28-04-2007 28-04-2007	27-04-2022 27.04.2022	08-12-2017 Pg.- 64	07-12-2019 pg. -64

Note: - Assisted in technical evaluation in reference to letter No-559(15), dated 26.6.2018 on the basis of documents provided by BMSICL in checklist-II, III & IV. Provided checklist compiled with due deligence and care. Inspite, some inadvertent discrepancies could have been crept in. Humble request to all concerned to bring to the notice in due time, if any discrepancies are observed, for rectification.

14/07/18